Ahead of presentations at the 6th Annual DDR Inhibitors Summit in Boston this week, Oren Gilad, Ph.D., president and CEO of Aprea, and Eric Brown, Ph.D., Scientific Consultant to Aprea, member of the company’s Scientific Advisory Board, and Associate Professor of Cancer Biology at the University of Pennsylvania, took time out to speak with BioBuzz about the company and the significance of new target and biomarker identification in oncology research.
ennovation Works, the 23-acre University of Pennsylvania property just across the Schuylkill River from the core campus, has long been a site for innovation. Home to a ferry business in the 18th century, a paint company in the 19th century, and a DuPont chemical research facility for much of the 20th century, the space underwent a further transformation in 2016 with the establishment of the Pennovation Center, an incubator for science and technology startups, many of which have their origins within the University. Last year, the 65,000 square foot Pennovation Lab opened, offering larger lab spaces for companies outgrowing their previous locations.
Catalent Launches New Service for End-to-End Supply Chain Case Management of Cell and Gene Therapies
Catalent, the leader in enabling the development and supply of better treatments for patients worldwide, today announced the launch of its new Case Management Service, which has been specifically designed to address the unique challenges associated with the safe and timely delivery of advanced therapies to patients by providing professional supply chain oversight from program start to finish.
In its quest to be one of the top Contract Development and Manufacturing Organizations in the world, the Center for Breakthrough Medicines (CBM) will implement a robust digital solutions system that will support end-to-end cell and gene therapy manufacturing processes.
The first gene therapy to be approved by the FDA occurred in late 2017. It was Spark Therapeutics’ Luxturna, approved for a rare, genetic form of blindness. Since then, a handful of additional gene therapies have been approved, including bluebird bio’s Zynteglo for beta-thalassemia, which is expected to launch in March 2023. The Alliance for Regenerative Medicine predicts five more gene therapies may be approved this year.
Sponsored by the not-for-profit Uplifting Athletes, the Young Investigators Draft provides $20,000 grants to 10 beginning-career stage research scientists in the rare disease community. The award is an unrestricted grant that will support the vital investigation of potential therapies and cures, including gene therapies, for rare disease, said Rob Long, executive director of Uplifting Athletes.
Focused on treating hypertension, Radnor, PA-based Mineralys Therapeutics filed with the SEC for an initial public offering (IPO). Although specifics of the launch have not been published, the company’s Filing Fee Table indicates the IPO could be for up to $100 million.
It has been another successful year for PQE Group, a consulting firm in the Life Sciences industry based in Florence (Italy) with 32 offices worldwide. Recently named “Best Managed Company” by Deloitte, the Group closed in 2022 with a +70% in revenues compared to the previous year, thanks to the tremendous growth in the US and other international markets.
Leap Therapeutics, headquartered in Cambridge, Mass., acquired New Hope, Pa.-based Flame Biosciences. The primary focus of the merger was for Leap to pick up Flame’s FL-301, a clinical-stage anti-Claudin18.2 monoclonal antibody.
In a wide-ranging discussion, the panel discussed how they got into working with mRNA, what they’ve seen as key drivers in the field (COVID-19, of course, was major), and what they’re excited to see in the future.